Experimental data indicate that CDKN1A is a p53 target and can stimulate apoptosisin tumor cells by activating the TNF receptor or the proapoptoticprotein BAX, or by modulating the intrinsicapoptotic pathway via changes in mitochondrial membranepermeability (Abbas, Dutta, 2009). The gene discussed is BAX; the disease is neoplasm.